Position Statement about Gender-Neutral HPV Vaccination in Korea

Area of Science:

• Public Health
• Vaccinology
• Oncology

Background:

• Rising incidence of human papillomavirus (HPV)-related diseases, including cervical, penile, and oropharyngeal cancers, necessitates proactive public health interventions.
• The burden of HPV-related cancers disproportionately affects certain demographics, highlighting the need for equitable prevention strategies.

Purpose of the Study:

• To advocate for the implementation of gender-neutral vaccination (GNV) for human papillomavirus (HPV) in South Korea.
• To recommend a comprehensive HPV vaccination strategy for both males and females to prevent a wide range of HPV-related conditions.

Main Methods:

• This position statement proposes the introduction of GNV, recommending HPV vaccine administration to individuals aged 9-26 years.
• Specific dosing schedules are advised: two doses for those aged 9-14 years and three doses for those aged 15-26 years.
• The optimal vaccination age is identified as 11-12 years, with provisions for vaccinating women aged 27 and older at healthcare provider discretion.

Main Results:

• The proposed GNV strategy aims to prevent a broad spectrum of HPV-related conditions.
• Implementation of GNV is expected to significantly curb the spread of HPV infections.
• Reduced incidence of HPV-related cancers is a projected outcome of widespread vaccination.

Conclusions:

• Gender-neutral vaccination (GNV) is essential for reducing the overall burden of HPV-related cancers in South Korea.
• The adoption of GNV represents a critical public health initiative for disease prevention.
• Comprehensive HPV vaccination strategies are vital for protecting both men and women from HPV-related diseases.